SARS-CoV-2 infection is the infectious disease COVID-19 caused by the SARS-CoV-2 virus. It continues to circulate globally and can cause severe acute illness as well as post-COVID conditions.
A study of nearly 70,000 children found girls exposed to SARS-CoV-2 infection in utero had a 44% increased risk of autism spectrum disorder. The research showed 3.97% of pregnant women had COVID-19 infection, with most cases occurring in the third trimester. No increased risk was observed for boys or for speech/language and motor delays overall.
New research from 18 countries shows COVID-19 vaccination during pregnancy, particularly with booster doses, significantly reduces the risk of preeclampsia and other serious complications for both mothers and babies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07430410 |
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test |
NOT_YET_RECRUITING | NA |
| NCT07300839 |
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07222384 |
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07086222 |
Efficacy and Safety of NVX-CoV2705 |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07079670 |
Safety and Immunogenicity of NVX-CoV2705 |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07069309 |
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07063134 |
Chronic Mouth Breathing and SARS-CoV-2 Positivity in the Pediatric Population |
COMPLETED | |
| NCT06917261 |
Evaluation of the Diagnostic Performance of the TestNPass DM-DIV for SARS-CoV-2 Using a Nasopharyngeal Sample |
COMPLETED | NA |
| NCT06810934 |
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses |
RECRUITING | PHASE1/PHASE2 |
| NCT06631287 |
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID |
RECRUITING | PHASE3 |
